Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic value of total, free and lipoprotein fraction-bound plasma mitotane levels in advanced adrenocortical carcinoma: a prospective study of the ENDOCAN-COMETE-Cancer network.
Faron M, Naman A, Delahousse J, Hescot S, Hadoux J, Castinetti F, Drui D, Renoult-Pierre P, Libe R, Lamartina L, Leboulleux S, Al-Ghuzlan A, Lombès M, Paci A, Baudin E; For Endocan-Comete Network. Faron M, et al. Among authors: al ghuzlan a. J Endocrinol Invest. 2024 Aug 22. doi: 10.1007/s40618-024-02439-7. Online ahead of print. J Endocrinol Invest. 2024. PMID: 39172357
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
Mauclère-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, Deandreis D, Drouard L, Tabarin A, Chanson P, Schlumberger M, Baudin E. Mauclère-Denost S, et al. Eur J Endocrinol. 2012 Feb;166(2):261-8. doi: 10.1530/EJE-11-0557. Epub 2011 Nov 2. Eur J Endocrinol. 2012. PMID: 22048971 Clinical Trial.
Recurrence-Free Survival Analysis in Locally Advanced Pheochromocytoma: First Appraisal.
Moog S, Castinetti F, DoCao C, Amar L, Hadoux J, Lussey-Lepoutre C, Borson-Chazot F, Vezzosi D, Drui D, Laboureau S, Raffin Sanson ML, Lamartina L, Pierre P, Batisse Ligner M, Hescot S, Al Ghuzlan A, Renaudin K, Libé R, Laroche S, Deniziaut G, Gimenez-Roqueplo AP, Jannin A, Leboulleux S, Guerin C, Faron M, Baudin E. Moog S, et al. J Clin Endocrinol Metab. 2021 Aug 18;106(9):2726-2737. doi: 10.1210/clinem/dgab202. J Clin Endocrinol Metab. 2021. PMID: 33782697
Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy.
Cosentini D, Grisanti S, Hadoux J, Libè R, Frigerio M, Laganà M, Deschamps F, Zamparini M, Lamartina L, Pedersini R, Valsecchi C, Maroldi R, Al Ghuzlan A, Terzolo M, Gasparotti R, Baudin E, Berruti A. Cosentini D, et al. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2167-e2176. doi: 10.1210/clinem/dgab899. J Clin Endocrinol Metab. 2022. PMID: 34905056 Free article.
Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival.
Hescot S, Faron M, Kordahi M, Do Cao C, Naman A, Lamartina L, Hadoux J, Leboulleux S, Pattou F, Aubert S, Scoazec JY, Al Ghuzlan A, Baudin E. Hescot S, et al. Cancers (Basel). 2022 Apr 29;14(9):2225. doi: 10.3390/cancers14092225. Cancers (Basel). 2022. PMID: 35565353 Free PMC article.
New endpoints in adrenocortical carcinoma studies: a mini review.
Faron M, Lamartina L, Hescot S, Moog S, Deschamps F, Roux C, Libe R, Durand-Labrunie J, Al Ghuzlan A, Hadoux J, Baudin E. Faron M, et al. Endocrine. 2022 Sep;77(3):419-424. doi: 10.1007/s12020-022-03128-2. Epub 2022 Jul 23. Endocrine. 2022. PMID: 35869971 Review.
101 results